Keywords: GlaxoSmithKline, Revolade, NICE, UK, Avandia, Side effects, USA

GlaxoSmithKline gets negative NICE appraisal for Revolade; another attack on safety of Avandia

Article | 11 June 2010

Print This

Just a day after GlaxoSmithKline received a refusal to fund National Health Service use of its breast cancer drug Tyverb ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in